GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioRestorative Therapies Inc (FRA:9OF) » Definitions » Cyclically Adjusted Price-to-FCF

BioRestorative Therapies (FRA:9OF) Cyclically Adjusted Price-to-FCF : (As of Jun. 16, 2024)


View and export this data going back to 2021. Start your Free Trial

What is BioRestorative Therapies Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


BioRestorative Therapies Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for BioRestorative Therapies's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioRestorative Therapies Cyclically Adjusted Price-to-FCF Chart

BioRestorative Therapies Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

BioRestorative Therapies Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of BioRestorative Therapies's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, BioRestorative Therapies's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioRestorative Therapies's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioRestorative Therapies's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where BioRestorative Therapies's Cyclically Adjusted Price-to-FCF falls into.



BioRestorative Therapies Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

BioRestorative Therapies's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, BioRestorative Therapies's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2023 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.361/129.4194*129.4194
=-0.361

Current CPI (Dec. 2023) = 129.4194.

BioRestorative Therapies Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201403 -2,429.167 99.695 -3,153.447
201406 -2,596.296 100.560 -3,341.415
201409 -2,087.097 100.428 -2,689.602
201412 -1,317.949 99.070 -1,721.699
201503 -1,852.381 99.621 -2,406.458
201506 -775.000 100.684 -996.187
201509 -706.000 100.392 -910.138
201512 -1,012.000 99.792 -1,312.449
201603 -1,624.000 100.470 -2,091.931
201606 -960.000 101.688 -1,221.801
201609 -1,103.000 101.861 -1,401.416
201612 -1,014.000 101.863 -1,288.315
201703 -1,140.000 102.862 -1,434.328
201706 -682.000 103.349 -854.038
201709 -427.000 104.136 -530.674
201712 -574.500 104.011 -714.841
201803 -469.500 105.290 -577.098
201806 -445.000 106.317 -541.698
201809 -580.000 106.507 -704.775
201812 -455.000 105.998 -555.538
201903 -438.000 107.251 -528.536
201906 -250.800 108.070 -300.347
201909 -259.000 108.329 -309.423
201912 -85.789 108.420 -102.405
202003 -1.018 108.902 -1.210
202006 -0.935 108.767 -1.113
202009 -1.113 109.815 -1.312
202012 -0.656 109.897 -0.773
202103 -0.861 111.754 -0.997
202106 -0.736 114.631 -0.831
202109 -0.614 115.734 -0.687
202112 -0.288 117.630 -0.317
202203 -0.439 121.301 -0.468
202206 -0.361 125.017 -0.374
202209 -0.396 125.227 -0.409
202212 -0.473 125.222 -0.489
202303 -0.605 127.348 -0.615
202306 -0.275 128.729 -0.276
202309 -0.244 129.860 -0.243
202312 -0.361 129.419 -0.361

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


BioRestorative Therapies  (FRA:9OF) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


BioRestorative Therapies Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of BioRestorative Therapies's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


BioRestorative Therapies (FRA:9OF) Business Description

Traded in Other Exchanges
Address
40 Marcus Drive, Suite One, Melville, NY, USA, 11747
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, primarily involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.

BioRestorative Therapies (FRA:9OF) Headlines

No Headlines